通过门诊切除术继续抗凝治疗不会影响术后出血风险
Colin M Cleary1, Emily Orosco1, James Gallagher2
1University of Connecticut School of Medicine, Farmington, CT.
Journal of vascular surgery. Venous and lymphatic disorders
|January 31, 2025
概括
对于门诊骨干切除术 (AP) 程序的持续抗凝药是安全的. 与未服用抗凝药的患者相比,接受抗凝药的患者没有出现增加的出血或不良事件.
科学领域:
- 血管外科 血管外科
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在外科手术过程中,抗凝血药经常被停止或过桥.
- 门诊性脑膜切除术 (AP) 是一种常见的门诊手术,用于静脉功能不充分.
- 在AP期间继续使用抗凝血剂的安全性尚未得到充分证实.
研究的目的:
- 为了比较患者接受AP的术后出血和主要不良事件与或没有慢性抗凝药.
- 评估在AP期间持续抗凝剂的安全性.
主要方法:
- 从2016年1月到2023年2月接受AP的患者的回顾性研究.
- 慢性抗凝剂治疗患者与未服用患者的16个人口参数的倾向性得分匹配.
- 术后出血,湿疹,疼痛,30天的急诊室访问和主要的不良心脏事件的比较.
主要成果:
- 两组之间在手术后出血,湿疹或疼痛方面没有显著差异.
- 在任何一组中都没有手术期间发生的重大出血事件,30天的急救诊所访问或重大不良心脏事件.
- 随着里瓦洛克萨班的使用,出现更高出血的趋势,尽管在统计学上并不显著.
结论:
- 在门诊骨干切除术期间继续使用慢性抗凝药是安全的.
- 可以在不中断抗凝血治疗的情况下进行 ambulant phlebectomy.
- 这种做法可能会减少对桥梁治疗的需要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Disorders of Hemostasis
688
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
688
Extrinsic and Intrinsic Pathways of Hemostasis
5.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
5.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
461
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
461
Esophageal Varices-II: Clinical Features and Management
37
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
37


